ASH 2014: Novartis's CAR-T therapy performs well in pediatric trial
This article was originally published in Scrip
Executive Summary
The enthusiasm about chimeric antigen receptor T-cell (CAR-T) therapies continued this year at the American Society of Hematology (ASH) annual meeting. Highlights from this therapeutic class included updated early clinical phase data for Novartis's Phase II CTL019,which has demonstrated promise in the treatment of patients with relapsed and refractory acute lymphocytic leukemia (ALL), including pediatric cases.